Sepsis is a systemic inflammatory response syndrome, mainly caused by endotoxemia, a condition characterized by the presence of endotoxins in the blood. Lipopolysaccharides (LPS) are lipid-containing polysaccharides that are endotoxins and important group-specific antigens. Sepsis is often associated with multiorgan dysfunctions especially of the heart. Myocardial dysfunction, also referred to as septic cardiomyopathy (SC), is a common complication of severe sepsis. The clinical manifestation of SC is systolic and diastolic dysfunction and is often accompanied by abnormal levels of cardiac biomarkers such as troponin and natriuretic peptides (NPs) in the setting of sepsis [1]. Up to 44% of patients with sepsis showed SC [1, 2], and their mortality rate was significantly higher than those without SC [3]. Septic cardiomyopathy is a multifactorial process that involves complex interactions between the host immune system and invading pathogens. Owing to the complex clinical manifestations, numerous assessment methods, and variations in the preseptic state of the heart, there is currently no consensus about a formalized definition of SC. The specific pathogenesis of SC might be related to the injury, necrosis, and apoptosis of myocardial cells, which could be caused by inflammatory factors [4, 5]. Other studies revealed that cardiomyocyte energy metabolism disorder [6], myocardial microcirculation dysfunction, and myocardial cell hypoxia injury also played important roles in the occurrence and development of SC [7], although the molecular mechanisms and their significance in the pathogenesis of SC are still not clear.

Wnt5a predominantly activates the β-catenin-independent Wnt signaling cascade including the Wnt/calcium and Wnt/PCP (Wnt/polarity) pathways. Recent studies showed that Wnt5a was induced by LPS in human macrophage and was found in the sera of patients with severe sepsis [10]. Some researchers thought Wnt5a was an inflammatory cytokine and could mediate the release of pro-inflammatory factors such as interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and interferons (IFN; [11–13]). Therefore, we hypothesized that Wnt5a may play a role in LPS-induced myocardial damage. C-jun N-terminal kinase (JNK) is a member of the mitogen-activated protein kinase (MAPK) family and is a type of serine/threonine protein kinase. It can regulate cell growth, differentiation, proliferation, inflammation, and apoptosis by phosphorylating c-jun or other substrates after activation [14]. The JNK signaling pathway mediates the production and release of inflammatory factors, which promotes the development of inflammation, in which the Wnt5a/JNK/nuclear factor kappa B (NF-κB) signaling cascade plays an important role [15–18]. NF-κB signaling pathway is upstream of the NF-κB signaling pathway. Lipopolysaccharide can activate JNK pathway, promote the transfer of NF-κB to the nucleus, further increase inflammatory factors, and induce injury and apoptosis of the cells. The specific JNK inhibitor, SP600125, can significantly inhibit the activation of JNK induced by LPS and reduce the phosphorylation level of NF-κB [19–22].

Alprostadil, also known as prostaglandin E1 (PGE1), is a potent vasodilator agent. Alprostadil has numerous effects including vasodilation, protecting endothelial cells, and inhibiting the activation and aggregation of neutrophils and thrombocytes [23]. Clinical research has demonstrated that alprostadil can reduce the expression of inflammatory factors such as myeloperoxidase (MPO), TNF-α, and IL-6 in the treatment of ischemia reperfusion injury, contrast nephropathy, and diabetic nephropathy etc. [24–27]. Furthermore, PGE1 improved the myocardial microcirculation and alleviated apoptosis of myocardial cells [28, 29]. These findings indicate that alprostadil may have an anti-inflammatory effect, although its molecular mechanisms are not exactly clear. This study investigated whether alprostadil has protective effects on LPS-induced injury in myocardial cells and elucidated its potential mechanisms.
**Materials and methods**

**Cell culture and treatments**

The H9c2 cardiomyoblasts were obtained from the Cell Bank of Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China) and cultured in Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum (Gibco, Rockville, MD, USA) in a humidified incubator with 5% CO2 at 37°C (Thermo Fisher Scientific, Waltham, MA, USA). Cells were seeded into 24-well plate and then cultured to the logarithmic growth phase (1.0×10⁵ cells/ml) and used for the experiment. The cells were treated with different concentrations of LPS (Sigma-Aldrich, St. Louis, MO, USA) at 10, 25, 50, 100 µg/l and/or alprostadil (Tide Pharmaceutical Co. Limited, Beijing, China) at 5 µg/l, 15 µg/l, and 45 µg/l for 3 h, 6 h, 12 h, and 24 h, respectively. The follow-up intervention concentration and time point were selected according to the results of subsequent 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) experiments. The siRNA interference sequence (Gima gene, Wuhan, Hubei, China) was designed according to the sequence of rat Wnt5a. Nonspecific siRNA (scramble) with non-targeting was used as a control. Cells grown to a confluence of 40–50% were transfected with siRNA using Lipofectamine 2000 reagent (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s protocol. The siWnt5a sequences were as follows: sense GGUCCUAGGUAUGAAUATT, antisense UUAUUCAUACCUAGGACCTT; 5.0 µM SP600125 (Sigma-Aldrich) and used for comparison between groups. SPSS

**ELISA detection**

Commercial kits (Nanjing Jiancheng Biology Engineering Institute, China) were used to detect biochemical indicators of cellular damage such as lactate dehydrogenase (LDH), troponin, and the production of inflammatory cytokines, including interleukin-1β (IL-1β), IL-6, IL-17, and TNF-α, which were in the cellular supernatant and were measured with a microplate reader (Thermo Fisher Scientific) according to the manufacturer’s instruction.

**RNA extraction and RT-PCR**

Total RNA of cells was extracted by using an RNA extraction kit (Invitrogen). The RNA concentration was quantified using a spectrophotometer (NanoDrop 2000; Thermo Fisher Scientific). Complementary DNA synthesis was performed by using a Prime Script RT Reagent Kit (Takara, Osaka, Japan). Quantitative real-time PCR was performed by using gene-specific primers and an SYBR Green PCR Master Mix (Takara) on a Roche Light Cycler 480 Real Time PCR System as follows: 95°C for 30 s, then 40 cycles of 95°C for 15 s, followed by 60°C for 30 min. Measurements were performed in triplicates and normalized to endogenous GAPDH levels. Relative fold change in expression was calculated by using the 2-ΔΔCt method. The sequences of primers for Wnt5a, JNK, NF-κB, β-actin, and Lamin B are provided in the supplementary material.

**Statistical analysis**

Each step of the experiment was repeated at least three times independently. The measurement data are expressed as mean ± standard deviation (SD). One-way analysis of variance (ANOVA) was used for comparison between groups. Tukey test was used for comparison between the two groups, and SPSS
Alprostadil attenuates LPS-induced cardiomyocyte injury by inhibiting the Wnt5a/JNK/NF-κB pathway

Abstract

**Background.** Clinical research has demonstrated that alprostadil has an anti-inflammatory effect; however, to date, its molecular mechanisms remain unclear. This study aimed to examine the anti-inflammatory activity and related mechanisms of alprostadil in lipopolysaccharide (LPS)-treated H9c2 cells.

**Methods.** Cell morphology was observed under an inverted light microscope, while cell viability was assessed with the 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay. Enzyme-linked immunosorbent assays (ELISA) were conducted to study biochemical indicators of cellular damage, such as released lactate dehydrogenase (LDH) and troponin, and inflammatory cytokine levels including interleukin-1β (IL-1β), IL-6, IL-17, and tumor necrosis factor-α (TNF-α). The mRNA expression levels of Wnt5a, c-jun N-terminal kinase (JNK), and nuclear factor kappa B (NF-κB) were further investigated by real-time quantitative polymerase chain reaction (RT-PCR). The effects of alprostadil on the Wnt5a/JNK/NF-κB pathway in H9c2 cells was examined by Western blotting.

**Results.** Alprostadil increased the cell viability of LPS-stimulated H9c2 cells, reduced LDH and troponin production, and attenuated IL-1β, IL-6, IL-17, and TNF-α secretion. Moreover, alprostadil reduced the mRNA expression of Wnt5a, JNK, and NF-κB and decreased the expression of NF-κB and the ratio of p-JNK/JNK in H9c2 cells treated with LPS. The siWnt5a or JNK inhibitor SP600125 significantly augmented the inhibitory effects of alprostadil on the Wnt5a/JNK/NF-κB pathway.

**Conclusion.** Our results show that alprostadil has anti-inflammatory effects and could attenuate LPS-induced injury in H9c2 cardiomyocytes via the Wnt5a/JNK/NF-κB pathway.

**Keywords** Vasodilators · Lipopolysaccharides · Myocytes · cardiac · Cell survival · Anti-inflammatory effects

---

**Alprostadil schwächt LPS-induzierte Kardiomyozytenenschäidigung durch Hemmung des Wnt5a/JNK/NF-κB-Signalwegs ab**

**Zusammenfassung**

**Hintergrund.** Klinische Untersuchungen haben gezeigt, dass Alprostadil einen antiinflammatorischen Effekt hat; jedoch sind die entsprechenden molekularen Mechanismen bisher nicht bekannt. Die vorliegende Studie hatte zum Ziel, die antiinflammatorische Aktivität und die Wnt5a/JNK/NF-κB-Signalwege von Alprostadil in Lipopolysaccharid (LPS)-behandelten H9c2-Zellen zu untersuchen.

**Methoden.** Unter dem Lichtmikroskop wurde die Zellmorphologie unter sucht, während die Lebensfähigkeit der Zellen mit dem 3-(4,5-Dimethylthiazolyl-2)-2,5-Diphenyltetrazoliumbromid (MTT)-Assay beurteilt wurde. Enzyme-linked-Immunosorbent-Assays (ELISA) wurden durchgeführt, um biochemische Indikatoren der Zellulären Schädigung zu untersuchen, z. B. freigesetzte Laktatdehydrogenase (LDH) und Troponin, sowie inflammatorische Zytokine sowie die Immunreaktion einschließlich Interleukin-1β (IL-1β), IL-6, IL-17 und Tumornekrosefaktor-α (TNF-α). Die Wnt5a, c-jun N-terminal Kinase (JNK) und der nukleare Faktor kappa B (NF-κB) wurden durch quantitative Polymerasekettenreaktion (RT-PCR) untersucht. Die Effekte von Alprostadil auf die Wnt5a/JNK/NF-κB-Signalwege in H9c2-Zellen wurden durch den Westernblottest ermittelt.

**Ergebnisse.** Alprostadil erhöhte die Lebensfähigkeit der Zellen von LPS-stimulierten H9c2-Zellen, verminderte die Produktion von LDH und Troponin und schwächte die Sekretion von IL-1β, IL-6, IL-17 und TNF-α ab. Darüber hinaus reduzierte Alprostadil die mRNA-Expression von Wnt5a, JNK und NF-κB sowie verminderte die Expression von Wnt5a, NF-κB und das Verhältnis von p-JNK/JNK in H9c2-Zellen, die mit LPS behandelt worden waren. Durch siWnt5a oder den JNK-Inhibitor SP600125 wurden die inhibitorischen Effekte von Alprostadil auf die Wnt5a/JNK/NF-κB-Signalweg signifikant verstärkt.

**Schlussfolgerung.** Die vorliegenden Ergebnisse zeigen, dass Alprostadil antiinflammatorische Effekte aufweist und die LPS-induzierte Schädigung von H9c2-Kardiomyozyten durch den Wnt5a/JNK/NF-κB-Signalweg abschwächen konnte.

**Schlüsselwörter** Vasodilatoren · Lipopolysaccharide · Myozyten · kardiale · Zellüberleben · Antiinflammatorische Effekte

---

**Results**

Alprostadil increased the viability of LPS-treated H9c2 cells

H9c2 cells were treated with different concentrations of LPS for 0h, 3h, 6h, 12h, and 24h. As shown in Fig. 1, it was found that LPS decreased cell proliferation with the prolongation of time. Results of the MTT assay showed that the cell viability gradually decreased with the increase in LPS concentration and time. Compared with other groups, 100 μg/l LPS had significant effects on H9c2 cell viability when treated for 12 and 24 h (p < 0.01; Fig. 2a); however, there was no statistically significant difference in cell viability between the 12-h and 24-h treatment. We observed effects of alprostadil on H9c2 cell activity treated with 100 μg/l LPS. Cells were pretreated with different doses of alprostadil and then treated with 100 μg/l LPS for 3h, 6h, 12h, and 24h. We found that cell viability was significantly restored by the pretreatment with alprostadil (Fig. 1). The cell viability gradually recovered in cells pretreated with 45 μg/l alprostadil for 12 and 24h (p < 0.01; Fig. 2b). These results indicate that alprostadil protected H9c2 cells against LPS-induced injury;
45 μg/l alprostadil was chosen and used in the following experiments.

Alprostadil ameliorated LPS-induced cell injury and downregulated the expression of inflammatory cytokines

Further, cell injury was examined by measuring LDH and troponin levels. It was found that LPS significantly increased the release of LDH in a time-dependent manner, which could be reversed significantly by pretreating with alprostadil \((p < 0.01; \text{ Fig. 3a})\). The LPS significantly increased troponin levels in H9c2 cell supernatant, but not in a significant time-dependent manner, and the troponin level was reduced by pretreat-
Fig. 3  
Effects of alprostadil on the release of (a) lactate dehydrogenase (LDH) and (b) troponin (TNI) in lipopolysaccharide (LPS)-treated H9c2 cells for 3 h, 6 h, and 12 h. Data are presented as means ± SD, and group differences were analyzed by one-way ANOVA with Tukey’s post hoc test, n = 3 independent experiments; asterisk p < 0.05, double asterisk p < 0.01.

Fig. 4  
Effects of alprostadil on the levels of lipopolysaccharide (LPS)-induced inflammatory cytokines in H9c2 cells subjected to treatment for 3 h, 6 h, and 12 h: a interleukin (IL)-1; b IL-6; c IL-17; d tumor necrosis factor (TNF)-α. Data are presented as means ± SD, and group differences were analyzed by one-way ANOVA with Tukey’s post hoc test, n = 3 independent experiments; asterisk p < 0.05, double asterisk p < 0.01.
Effects of alprostadil on LPS-induced mRNA expression of Wnt5a, JNK, and NF-κB in H9c2 cardiomyocytes

To investigate the potential signaling pathways involved in LPS-induced injury in H9c2 cardiomyocytes, we first examined the relative mRNA expression in H9c2 cells treated by LPS, including Wnt5a, JNK, and NF-κB. As shown in Fig. 5, Wnt5a, JNK, and NF-κB mRNA expression was significantly elevated in response to LPS treating after 3 h ($p < 0.01$). By contrast, pretreatment with alprostadil markedly reduced their expression ($p < 0.01$). Wnt5a siRNA was then used to treat H9c2 cells. It was found that siWnt5a specifically down-regulated the expression level of Wnt5a ($p < 0.01$), while JNK and NF-κB mRNA expression was also reduced ($p < 0.01$, $p < 0.01$, respectively) after treatment with LPS. Moreover, the mRNA level of Wnt5a, JNK, and NF-κB showed a much greater significant decrease in the LPS+siWnt5a+alprostadil group ($p < 0.001$, $p < 0.001$, $p < 0.01$, respectively), indicating that alprostadil might play a role by simulating Wnt5a, and that alprostadil combined with siWnt5a can exert synergistic inhibitory effects on the mRNA expression of Wnt5a, JNK, and NF-κB.

Furthermore, H9c2 cells were treated with SP600125, an inhibitor of JNK signaling. The data showed that the mRNA expression of Wnt5a, JNK, and NF-κB were significantly decreased in the LPS+SP600125 group compared with the LPS group ($p < 0.01$, $p < 0.01$, $p < 0.01$, respectively) and their expression was further decreased in the group pretreated with alprostadil and SP600125 ($p < 0.01$, $p < 0.01$, $p < 0.01$ respectively). The mRNA expression levels of Wnt5a, JNK, and NF-κB were still high in the SP600125 group and SP600125+alprostadil group compared...
Fig. 6 Alprostadil suppresses Wnt5a/JNK/NF-κB signaling in LPS-induced H9c2 cells. Western blot analysis was conducted using specific antibodies against Wnt5a, JNK, and NF-κB (a–d). 1 control group, 2 alprostadil group, 3 LPS group, 4 LPS+alprostadil group, 5 LPS+siWnt5a group, 6 LPS+siWnt5a+alprostadil group, 7 LPS+SP600125 group, 8 LPS+SP600125+alprostadil group. Data are presented as means±SD, and group differences were analyzed by one-way ANOVA with Tukey’s post hoc test, n = 3 independent experiments; asterisk p < 0.05; double asterisk p < 0.01; triple asterisk p < 0.001.

with the alprostadil group, siWnt5a group, and LPS+siWnt5a+alprostadil group (data not shown). Therefore, we speculated that SP600125 had an inhibitory effect on gene transcription levels of Wnt5a, JNK, and NF-κB, and that alprostadil could further enhance this inhibitory effect, but SP600125 was weaker than alprostadil and much weaker than siWnt5a.

**Alprostadil suppresses Wnt5a/JNK/NF-κB signaling in H9c2 cardiomyocytes treated with LPS**

We explored the protein expression of Wnt5a, JNK, p-JNK, and NF-κB in H9c2 cells treated with LPS by Western blotting. As shown in Fig. 6, LPS treatment remarkably increased the expression of Wnt5a, NF-κB, and the ratio of p-JNK/JNK (p < 0.001, p < 0.05, p < 0.05, respectively), while pretreatment with alprostadil reduced the expression of Wnt5a, NF-κB, and the ratio of p-JNK/JNK (p < 0.001, p < 0.05, p < 0.05, respectively). Next, siWnt5a was used to pretreat cells, and it was found that the expression of NF-κB (p < 0.01) and the ratio of p-JNK/JNK (p < 0.05) were lower in the LPS+siWnt5a group than that in the LPS+alprostadil group. However, there was no significant difference in the expression of Wnt5a in the LPS+siWnt5a group and LPS+alprostadil group. Moreover, it was found that the expression of Wnt5a, NF-κB, and the ratio of p-JNK/JNK (p < 0.001, p < 0.05, p < 0.05, respectively) further decreased in the group pretreated with siWnt5a and alprostadil compared with the LPS+siWnt5a group. Based on these results, it was considered that alprostadil alone had no significant effect on the Wnt5a/JNK/NF-κB signaling pathway. The Wnt5a/JNK/NF-κB pathway was activated by LPS and inhibited by pretreatment with alprostadil in a similar way to siWnt5a. Besides, alprostadil combined with siWnt5a exerted a synergistic inhibitory effect on the Wnt5a/JNK/NF-κB signaling pathway activated by LPS. SP60025 was used to further investigate the underlying mechanisms of alprostadil inhibition of Wnt5a/JNK/NF-κB signaling in LPS-induced cardiomyocytes. We found that the expression of Wnt5a, NF-κB, and the ratio of P-JNK/JNK were significantly decreased in the LPS+SP60025 group (p < 0.01, p < 0.05, p < 0.05, respectively) compared with the LPS group, and their expression was further decreased in the group pretreated with SP600125 and alprostadil (p < 0.01, p < 0.01, p < 0.01, respectively) compared with the LPS+SP600125 group. Interestingly, it was found that the NF-κB level...
was higher in the LPS+SP60025 group than that in the LPS+siWnt5a group and the LPS+siWnt5a+alprostadil group \((p<0.05)\), indicating that SP600125 inhibited the Wnt5a/JNK/NF-κB signaling pathway and showed a synergistic effect with alprostadil. Phosphorylated JNK exhibited the Wnt5a/JNK/NF-κB signaling pathway and showed a synergistic effect in adose-dependent and time-dependent manner, in which high concentrations of LPS (100 μg/l) significantly increased myocardial cell injury markers such as LDH and troponin as well as inflammatory factors such as IL-1, IL-6, IL-17, and TNF-α in myocardial cells. These results indicate that LPS led directly to cell injury in a dose-dependent manner.

Wnt5a, a secretory glycoprotein that is mainly involved in nonclassic pathways, is an inflammatory response molecule derived from macrophages. It can stimulate the release of other inflammatory response factors through autocrine or paracrine signaling [42]. Moreover, Wnt5a activates the downstream JNK/NF-κB signaling pathway, is involved in crosstalk with other signaling pathways, and plays a role in cellular inflammatory responses. Wnt5a can be induced by LPS/IFN-γ in human macrophages [11–13]. In our study we also found that LPS induced H9c2 cells to secrete Wnt5a, elevated the JNK phosphorylation level, and increased the amount of NF-κB in the nuclei, which was reversed by the application of siWnt5a. These results suggest that LPS could activate the Wnt5a/JNK/NF-κB pathway in H9c2 cells. Pretreatment with SP60025 significantly reduced the amount of NF-κB in the nucleus, which, however, was still higher than in the siWnt5a group. These results suggest that NF-κB may also be regulated by other signaling pathways besides JNK.

Alprostadil can protect the microcirculation and inhibit inflammatory responses, and, as is known, have anti-inflammatory and anti-apoptotic effects on the myocardium [24–27]. We found that alprostadil reversed the decline of cell activity, reduced LDH and troponin levels, and down-regulated the expression of inflammatory factors in H9c2 cells treated with LPS, which suggests that alprostadil had a protective effect on myocardial cells. Following this, we explored its mechanisms. The expression levels of Wnt5a, NF-κB, and p-JNK/JNK did not change significantly when treated with alprostadil alone, indicating that alprostadil did not have significant influence on the Wnt5a/JNK/NF-κB signaling pathway in cardiac cells without LPS stimulation. However, it was observed that alprostadil decreased the mRNA levels of Wnt5a, JNK, and NF-κB in H9c2 cells treated with LPS, as well as the protein levels of Wnt5a, p-JNK/JNK, and NF-κB in the nucleus, respectively, indicating that alprostadil had an inhibitory effect on the Wnt5a/JNK/NF-κB pathway activated by LPS. Next, H9c2 cells were pretreated with siWnt5a, and it was found that siWnt5a had a similar inhibitory effect on the Wnt5a/JNK/NF-κB signaling pathway to alprostadil. These results indicate that alprostadil might play a role by inhibiting Wnt5a in the Wnt5a/JNK/NF-κB pathway. Moreover, it was found that alprostadil combined with siWnt5a or SP60025 could further inhibit the Wnt5a/JNK/NF-κB pathway activated by LPS, thereby playing a cellular protective role. Collectively, it was demonstrated that alprostadil exerted its potential protection against LPS-induced injury of H9c2 cardiomyocytes via the Wnt5a/JNK/NF-κB pathway.

**Discussion**

Sepsis is a systemic inflammatory response syndrome (SIRS) usually caused by endotoxin [30]. Myocardial injury, known as septic cardiomyopathy (SC), is one of the most serious complications of sepsis. The exact mechanism of SC remains unclear; it has been found that endotoxin and inflammatory molecules may be responsible for myocardial injury, derangement in cardiomyocyte physiology at the microcirculatory level, mitochondrial dysfunction, disruption of normal calcium handling, and autophagy deficiency [4, 5, 31]. The conventional therapy for septic cardiomyopathy includes fluid resuscitation and administration of vasopressors. Cardiac inotropes such as levosimendan, a calcium sensitizer, may improve myocardial contractility in the absence of increased oxygen consumption and may also be useful for septic cardiomyopathy [32], but this view remains controversial [33]. Other studies have shown that veno-arterial extracorporeal membrane oxygenation (ECMO) or intra-aortic balloon pumping (IABP) was beneficial for patients with severe septic cardiomyopathy [34, 35]. Some studies reported that the cardiac function of patients suffering from sepsis could recover fully to the premorbid state [36, 37] and the reversibility in SC may be similar to myocardial ischemia preconditioning [38, 39]. Honda et al. found that remote ischemic conditioning (RIC), a highly cardioprotective phenomenon induced by repeated transient ischemia of a remote organ or tissue, reduced circulating inflammatory mediators associated with septic cardiomyopathy, suppressed inflammatory signaling pathways in heart tissue, reduced cardiac damage, and consequently preserved ventricular function in models as described previously [41]. It was observed that the cell viability gradually decreased after treatment with LPS in a dose-dependent and time-dependent manner, in which high concentrations of LPS (100 μg/l) significantly increased myocardial cell injury markers such as LDH and troponin as well as inflammatory factors such as IL-1, IL-6, IL-17, and TNF-α in myocardial cells. These results indicate that LPS led directly to cell injury in a dose-dependent manner.

Wnt5a, a secretory glycoprotein that is mainly involved in nonclassic pathways, is an inflammatory response molecule derived from macrophages. It can stimulate the release of other inflammatory response factors through autocrine or paracrine signaling [42]. Moreover, Wnt5a activates the downstream JNK/NF-κB signaling pathway, is involved in crosstalk with other signaling pathways, and plays a role in cellular inflammatory responses. Wnt5a can be induced by LPS/IFN-γ in human macrophages [11–13]. In our study we also found that LPS induced H9c2 cells to secrete Wnt5a, elevated the JNK phosphorylation level, and increased the amount of NF-κB in the nuclei, which was reversed by the application of siWnt5a. These results suggest that LPS could activate the Wnt5a/JNK/NF-κB pathway in H9c2 cells. Pretreatment with SP60025 significantly reduced the amount of NF-κB in the nucleus, which, however, was still higher than in the siWnt5a group. These results suggest that NF-κB may also be regulated by other signaling pathways besides JNK.

Alprostadil can protect the microcirculation and inhibit inflammatory responses, and, as is known, have anti-inflammatory and anti-apoptotic effects on the myocardium [24–27]. We found that alprostadil reversed the decline of cell activity, reduced LDH and troponin levels, and down-regulated the expression of inflammatory factors in H9c2 cells treated with LPS, which suggests that alprostadil had a protective effect on myocardial cells. Following this, we explored its mechanisms. The expression levels of Wnt5a, NF-κB, and p-JNK/JNK did not change significantly when treated with alprostadil alone, indicating that alprostadil did not have significant influence on the Wnt5a/JNK/NF-κB signaling pathway in cardiac cells without LPS stimulation. However, it was observed that alprostadil decreased the mRNA levels of Wnt5a, JNK, and NF-κB in H9c2 cells treated with LPS, as well as the protein levels of Wnt5a, p-JNK/JNK, and NF-κB in the nucleus, respectively, indicating that alprostadil had an inhibitory effect on the Wnt5a/JNK/NF-κB pathway activated by LPS. Next, H9c2 cells were pretreated with siWnt5a, and it was found that siWnt5a had a similar inhibitory effect on the Wnt5a/JNK/NF-κB signaling pathway to alprostadil. These results indicate that alprostadil might play a role by inhibiting Wnt5a in the Wnt5a/JNK/NF-κB pathway. Moreover, it was found that alprostadil combined with siWnt5a or SP60025 could further inhibit the Wnt5a/JNK/NF-κB pathway activated by LPS, thereby playing a cellular protective role. Collectively, it was demonstrated that alprostadil exerted its potential protection against LPS-induced injury of H9c2 cardiomyocytes via the Wnt5a/JNK/NF-κB pathway.

**Conclusion**

The application of alprostadil can reduce the increase in cytokine levels and cell damage caused by lipopolysaccharides in H9c2 cardiomyocytes. The anti-inflammatory effects may be generated by inhibiting the Wnt5a/JNK/NF-κB pathway.

**Corresponding address**

Q. Wang  
Department of Emergency, Affiliated Hospital of Qingdao University  
Jiangsu Road No. 16, Qingdao, Shandong, China  
chasetiti@139.com

**Funding.** This work was supported by the National Key Research and Development Program of China [grant number 2017YFC1307701].
Compliance with ethical guidelines

Conflict of interest  T. Yu, D. Dong, J. Guan, J. Sun, M. Guo, and Q. Wang declare that they have no competing interests.

For this article no studies with human participants or animals were performed by any of the authors. All studies performed were in accordance with the ethical standards indicated in each case.

Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/ 4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References
1. Ehrman RR, Sullivan AN, Favot MJ et al (2018) Pathophysiology, echocardiographic evaluation, biomarker findings, and prognostic implications of septic cardiomyopathy: A review of the literature. Crit Care 22(1):112
2. Brunkhorst FM, Reinhart K (2009) Diagnosis and causal treatment of sepsis. Intensive 50:810–816
3. Kakkahana Y, Ito T, Nakahara M et al (2016) Sepsis-induced myocardial dysfunction: Pathophysiology and management. J Intensive Care 4:22
4. Court O, Kumar A, Parrillo JE et al (2002) Clinical review: Myocardial depression in sepsis and septic shock. Crit Care 6:500–508
5. Yin HY, Wei JR, Zhang R et al (2002) Effect of glutamine on caspase-3 mRNA and protein expression in the myocardium of rats with sepsis. Am J Med Sci 328:315–318
6. Wang X, Liu D, Chai W et al (2015) The role of uncoupling protein 2 during myocardial dysfunction in a canine model of endotoxin shock. Shock 43:292–297
7. Ellis CG, Bateman RM, Sharpe MD et al (2002) Effect of a maldistribution of microvascular blood flow on capillary O2 extraction in sepsis. Am J Physiol Heart Circ Physiol 282:H156–H164
8. Sen M, Ghosh G (2008) Transcriptional outcome of Wnt-Frizzled signal transduction in inflammation: Evolving concepts. J Immunol 181:4441–4445
9. George SJ (2008) Wnt pathway: A new role in regulation of inflammation. Arterioscler Thromb Vasc Biol 28:400–402
10. Pereira C, Schaer DJ, Bachl EB et al (2008) Wnt5a/ CaMKII signaling contributes to the inflammatory response of macrophages and is a target for the anti-inflammatory action of activated protein C and interleukin-10. Arterioscler Thromb Vasc Biol 28:504–510
11. Hallesko C, Dijkstraus JP, Kilander MB et al (2012) HeterotrimERIC G protein-dependent WNT-5A signaling to ERK1/2 mediates distinct aspects of microglia proinflammatory transformation. J Neuroinflammation 9:111
12. Catalán V, Gómez-Ambrosí J, Rodríguez A et al (2014) Activation of non-canonical Wnt signaling through Wnt5a in visceral adipose tissue of obese subjects is related to inflammation. Clin Endocrinol Metab 59:E1407–E1417
13. Naskar D, Maiti G, Chakraborty A et al (2014) Wnt5a-Rac1-NF-kappaB homeostatic circuitry sustains innate immune functions in macrophages. J Immunol 192:4386–4397
14. Cargnello M, Roux PP (2011) Activation and function of the MAPKs in visceral adipose tissue of obese subjects, the MAPK-activated protein kinases. Microbiol Mol Biol Rev 75(1):50–83
15. Jung YS, Lee HY, Kim SD et al (2013) Wnt5a stimulates chemotactic migration and chemokine production in human neutrophils. Exp Mol Med 45(6):e27
16. Zhao C, Bu X, Wang W et al (2014) GEC-derived SFRPs inhibits Wnt5a-induced macrophage chemotaxis and activation. PLoS ONE 9:e85058
17. Rauner M, Stein N, Winzer M et al (2012) Wnt5a is induced by inflammatory mediators in bone marrow stromal cells and regulates cytokine and chemokine production. J Bone Miner Res 27:575–585
18. Li B, Zhong L, Yang X et al (2011) Wnt5a signaling contributes to Abeta-induced neuroinflammation and neurotoxicity. PLoS ONE 6:e22920
19. Srisook N, Manhong S, Chiranthanut N et al (2019) Anti-inflammatory effect of trans-4- methoxycinnamaldehyde from Etingeria pavieana in LPS-stimulated macrophages mediated through inactivation of NF-xB and JNK/c-Jun signaling pathways and in rat models of acute inflammation. Toxicol Appl Pharmacol 371:3–11
20. Lee JW, Kim NH, Kim JY et al (2013) Aromadendrin inhibits lipopolysaccharide-induced nuclear translocation of NF-xB and phosphorylation of JNK in RAW 264.7 macrophage. Biomol Ther (Seoul) 21:216–221
21. Janss KA, Albeck JG, Peng LX et al (2003) A high throughput quantitative multiplex kinase assay for monitoring information flow in signaling networks: application to sepsis-apoptosis. Mol Cell Proteomics 2:463–473
22. Ghosh J, Das J, Manna P et al (2009) Taurine prevents arsenic-induced cardiac oxidative stress and apoptotic damage: Role of NF-xB and JNK MAPK pathway. Toxicol Appl Pharmacol 240:73–87
23. Zhao XS, Pan W, Bekeredjian R et al (2014) Endogenous endothelin-1 is required for cardiomyocyte survival in vivo. Circulation 114:830–837
24. San Norberto Garcia EM, Taylor JH, Cenizo N et al (2014) Beneficial effects of intra-arterial and intravenous prostaglandin E1 in intestinal ischemia-reperfusion injury. Interact Cardiovasc Thorac Surg 18:466–474
25. Hong Y, Peng J, Cai X et al (2017) Clinical efficacy of alprostadil combined with a-lipoic acid in the treatment of elderly patients with diabetic nephropathy. Open Med (Wars) 12:322–327
26. Qin L, Qin W, Wang J et al (2017) Combined treatment of diabetic nephropathy with alprostadil and calcium dobesilate. Exp Ther Med 14:5012–5016
27. Jia C, Dai C, Bu X et al (2012) Co-administration of prostaglandin E1 with somatostatin attenuates acute liver damage after massive hepatectomy in rats via inhibition of inflammatory responses, apoptosis and endoplasmic reticulum stress. Int J Mol Med 34:516–522
28. WeilF, Fu XR, Li W et al (2015) Effect of intravenous administration of liposomal prostaglandin E1 on microcirculation in patients with ST elevation myocardial infarction undergoing primary percutaneous intervention. Chin Med J (Engl) 128:1147–1150
29. Zhu H, Ding Y, Xu X et al (2017) Prostaglandin E1 protects coronary microvascular function via the glycogen synthase kinase 3b-mitochondrial permeability transition pore pathway in rat hearts subjected to sodium laurate-induced coronary microembolization. Am J Transl Res 9:2520–2534
30. Pickers K, Vassiliou T, Litgus V et al (2019) Sepsis management with a blood purification membrane: European experience. Blood Purif 47(Suppl 3):1–9
31. Li F, Sang F, Zhang H et al (2016) Role of TFE3 mediated autophagy, oxidative stress, inflammation, and cell death in endothixinduced myocardial toxicity of young and aged mice. Oxid Med Cell Longev 2016:380319
32. Zangrillo A, Putzu A, Monaco F et al (2015) Levosimendan reduces mortality in patients with severe sepsis and septic shock: A meta-analysis of randomized trials. J Crit Care 30(5):908–913
33. Chang W, Xie JF, Xu JY et al (2018) Effect of levosimendan on mortality in severe sepsis and septic shock: A meta-analysis of randomised trials. BMJ Open 8(3):e019338
34. Brechot N, Luyt CE, Schmidt Me et al (2013) Venoarterial extracorporeal membrane oxygenation support for refractory cardiovascular dysfunction during severe bacterial septic shock. Crit Care Med 41:1616–1626
35. Nakamura K, Doi K, Inokuchi R et al (2013) Endothxin adsorption by polymyxin B column or intraaortic balloon pumping use for severe septic cardiomyopathy. Am J Emerg Med 31:893.e1–893.e3
36. Sato R, Nau M (2015) A review of sepsis-induced cardiomyopathy. JIntensive Care 3:48
37. Jardin F, Fourme T, Page B et al (1999) Persistent preload defect in severe sepsis despite fluid loading: A longitudinal echocardiographic study in patients with septic shock. Chest 116(5):1354–1359
38. Levy RJ, Piel DA, Acton PD et al (2005) Evidence of myocardial hibernation in the septic heart. Crit Care Med 33(12):2752–2756
39. Budgingi GR, Duranteau J, Chandel NS et al (1998) Hibernation during hypoxia in cardiomyocytes. Role of mitochondria as the O2 sensor. J Biol Chem 273(6):3325–3326
40. Honda T, He Q, Wang F et al (2019) Acute and chronic remote ischemic conditioning attenuate septic cardiomyopathy, improve cardiac output, protect systemic organs, and improve mortality in a lipopolysaccharide-induced sepsis model. Basic Res Cardiol 114(3):15
41. Franceschelli S, Pesce M, Ferrone A et al (2017) Biological effect of licochalcone C on the regulation of PI3K/Akt/eNOS and NF-xB/iNOS/iNOS signaling pathways in H9c2 cells in response to LPS stimulation. Int J Mol Sci 18:E690
42. Kim J, Kim J, Kim DW et al (2010) Wnt5a induces endothelial inflammation via β-catenin-independent signaling. J Immunol 185:1274–1282